Loading...
NPI 1306870837 · Chicago, IL · Medical Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Mary Mulcahy is a medical oncology physician provider located in Chicago, Illinois. This profile covers 56 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Mary Mulcahy |
| Address | 675 N Saint Clair St |
| City | Chicago |
| State | IL |
| ZIP | 60611 |
| Taxonomy | Medical Oncology Physician |
| NPI Enumerated | July 10, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.2M |
| Medicaid | $51.3K |
This profile is consistent with a medical oncology infusion practice: the provider’s top Medicare revenue drivers are oncology and biologic drug codes such as J9144 ($1.3M, 40.9% of Medicare revenue), J9271 ($309.6K, 9.8%) and J1569 ($287K, 9.1%), and several other high-cost injectables (e.g., J9299, J9047) appear in the top Medicare list. The mix of checkpoint inhibitors, monoclonal antibodies, and immune globulin indicates routine administration of specialty infusion therapies and associated supportive care.
Medicare revenue is highly concentrated: the precomputed top-3 Medicare codes account for 59.7% of the provider’s total Medicare revenue, with J9144 alone representing $1.3M of the $3.2M Medicare total. That concentration means changes in reimbursement or utilization for a small set of biologic drugs would have outsized impact on overall Medicare revenue.
Medicaid billing is extremely concentrated around chemotherapy administration and related infusion services: the precomputed top-3 Medicaid codes account for 97.1% of the provider’s $51.3K Medicaid revenue, led by 96413 ($36.5K, 70.9%), followed by 99214 ($9.2K, 17.9%) and 96375 ($4.3K, 8.3%). This indicates the provider’s Medicaid activity is almost entirely clinical infusion and E/M encounters tied to chemotherapy delivery rather than a broader outpatient mix.
The provider is effectively Medicare-dominant on a scale basis: total Medicare revenue of $3.2M dwarfs Medicaid revenue of $51.3K, so payers and network managers should treat Medicare trends as the primary driver of the practice’s financial performance. Medicaid represents only a marginal share of lifetime reported public-payer revenue and would have limited immediate operational leverage.
At the national level the provider shows a marked outlier position for a single drug: J9144 ranks #8 of 615 providers nationally (99th percentile) and is labeled an "extreme outlier, far above typical national volume for this code," indicating unusually high daratumumab administration relative to peers. By contrast, other high-revenue Medicare drug codes show typical or modest standing (for example, J9271 ranks #1504 of 1841, 18th percentile and is described as typical/unremarkable), so the provider is a dominant national player for one specific infusion product while remaining more typical across other agents.
Complex evaluation-and-management and advanced infusion services are also notable elements of the practice: 99215 appears in the Medicare top codes with $51.1K and ranks #4150 of 145531 providers nationally (97th percentile; described as notably above typical national volume), and G0498 appears with $30.9K and ranks #29 of 896 (97th percentile; notably above typical). These standings suggest a higher-than-typical share of complex office visits and office-initiated infusion management relative to many peers.
The provider’s drug mix includes use of biosimilars and supportive agents alongside high-cost immunotherapies — for example Q5107 ($81.4K, 2.6%) and Q5119 ($63.9K, 2.0%) appear in the Medicare top-25 and sit at middle-to-upper percentiles nationally, while J9299 ($284.2K, 9.0%) and other branded agents are major revenue contributors. This combination suggests operational experience managing both originator biologics and biosimilar products within an infusion practice, which may influence formulary and contracting considerations.
The provider has long tenure on file (NPI enumerated 2006-07-10, ~20 years ago), consistent with an established outpatient oncology operation that has built a Medicare-oriented revenue base over time. Longevity plus the concentrated Medicare revenue profile suggests existing referral patterns and treatment lines that favor continued specialty infusion volumes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
56 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 34,020 | $40 | $1.3M |
| J9271 | Injection, pembrolizumab, 1 mg | 7,200 | $40 | $309.6K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 8,200 | $40 | $287K |
| J9299 | Injection, nivolumab, 1 mg | 11,840 | $20 | $284.2K |
| J2353 | Injection, octreotide, depot form for intramuscular injection, 1 mg | 840 | $160 | $136.1K |
| J0897 | Injection, denosumab, 1 mg | 6,960 | $20 | $132.2K |
| J9022 | Injection, atezolizumab, 10 mg | 2,020 | $60 | $129K |
| J9047 | Injection, carfilzomib, 1 mg | 3,490 | $40 | $125.7K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 3,540 | $20 | $81.4K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,200 | $20 | $63.9K |
Showing 1–10 of 56
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 56 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
56 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 74 | 110 | 11,600 | $40 | $564.2K |
| J9144 | 1 | 50 | 7,740 | $40 | $341.8K |
| J9299 | 11 | 30 | 9,570 | $20 | $305.2K |
| J9022 | 4 | 10 | 2,860 | $60 | $188.9K |
| J1569 | 5 | 50 | 2,730 | $40 | $143K |
| J2353 | 2 | 10 | 790 | $160 | $124.6K |
| J9047 | 3 | 10 | 2,070 | $40 | $108.9K |
| J0897 | 69 | 410 | 2,520 | $20 | $90.8K |
| Q5119 | 6 | 40 | 1,970 | $20 | $50.6K |
| J0881 | 37 | 70 | 11,600 | $1 | $38.2K |
Showing 1–10 of 56
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 720 | $50 | $36.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 190 | $50 | $9.2K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 270 | $20 | $4.3K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 20 | $60 | $990 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 20 | $10 | $240 |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 10 | $10 | $200 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 90 | $1 | $90 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 8,686 | 14,680 | 300 | $50 | $48.7K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 37 | 150 | 170 | $50 | $39.9K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 43 | 40 | 280 | $30 | $17.4K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 11 | 20 | 100 | $30 | $17.4K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 28 | 80 | 120 | $20 | $17.1K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 1,912 | 2,320 | 70 | $50 | $13.8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 73 | 140 | 90 | $1 | $480 |
Other providers in the same ZIP code as Mary Mulcahy, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ann & Robert H. Lurie Children's Hospital Of Chicago | IL | Children's Hospital | $0 | $7.1M |
| Rehabilitation Institute Of Chicago | IL | Rehabilitation Hospital | $0 | $7M |
| Integrated Rehab Consultants LLC | IL | Physical Medicine & Rehabilitation Physician | $0 | $4.3M |
| Rukhsana Mirza | IL | Ophthalmology Physician | $1.8M | $276.8K |
| Jayesh Mehta | IL | Hematology (Internal Medicine) Physician | $1.9M | $204.4K |
| Sheetal Kircher | IL | Medical Oncology Physician | $1.6M | $6.7K |
| Manjot Gill | IL | Ophthalmology Physician | $1.4M | $240.5K |
| Arthur Mandelin | IL | Rheumatology Physician | $1.2M | $361.3K |
| Jaideep Sohi | IL | Nuclear Radiology Physician | $1.5M | $6.9K |
| Alice Lyon | IL | Ophthalmology Physician | $1.4M | $30K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.